



DiagnosTear Ltd. – Approval to register patent to its TeaRx™ technology by the United States Patent and Trademark Office (USPTO)

Tel Aviv (October 15, 2019) – BioLight is pleased to announce that its subsidiary, DiagnosTear Ltd. ("**DiagnosTear**")¹, that is engaged in research, development and commercialization of a product that is based on DiagnosTear's TeaRx™ technology, which is used to diagnose, personalize treatment and monitor dry eye syndrome by examining the composition of the tear film ("**Diagnostear Product**" and the "**TeaRx™ technology**"), announced that it received an approval to register a patent from the United States Patent and Trademark Office (USPTO) (the "**Patent**").

The Patent joins similar patent approval that was received by the European Patent Office last July and constitutes part of family of patent registration applications that were submitted in several markets, the main one being the United States. The Patent protects the algorithm at the core of the Diagnostear Product and is based on the TeaRx Technology™ owned by Diagnostear.

The Patent strengthens and thickens the IP protection of the Diagnostear Product, the TeaRx™ Technology and the competitive position of Diagnostear.

The expected expiration date of the Patent, after registering, is May 2, 2036. The Patent is subject to payment of registration fee, as customary.

¹ Holding via XL Vision Sciences Ltd. (wholly owned subsidiary) approx. 89% of the issued and share capital of Diagnostear (approx. 86% fully diluted).

